KYMR
Kymera Therapeutics Inc

844
Mkt Cap
$6.24B
Volume
1.21M
52W High
$103.00
52W Low
$19.45
PE Ratio
-21.97
KYMR Fundamentals
Price
$79.49
Prev Close
$79.02
Open
$78.75
50D MA
$76.28
Beta
1.66
Avg. Volume
740,695.65
EPS (Annual)
-$2.98
P/B
5.99
Rev/Employee
$250,382.98
$2,618.04
Loading...
Loading...
News
all
press releases
Kymera Therapeutics (NASDAQ:KYMR) Receives Buy Rating from BTIG Research
BTIG Research reaffirmed a "buy" rating and issued a $138.00 price objective on shares of Kymera Therapeutics in a research note on Tuesday...
MarketBeat·7d ago
News Placeholder
More News
News Placeholder
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of "Buy" by Brokerages
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) has been given a consensus recommendation of "Buy" by the twenty-two brokerages that are presently covering the company, Marketbeat Ratings...
MarketBeat·9d ago
News Placeholder
Knights of Columbus Asset Advisors LLC Acquires New Holdings in Kymera Therapeutics, Inc. $KYMR
Knights of Columbus Asset Advisors LLC bought a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the third quarter, according to the company in its most recent...
MarketBeat·9d ago
News Placeholder
Federated Hermes Inc. Makes New Investment in Kymera Therapeutics, Inc. $KYMR
Federated Hermes Inc. bought a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the third quarter, according to its most recent filing with the Securities...
MarketBeat·10d ago
News Placeholder
KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate
Kymera Therapeutics begins phase IIb dosing of oral KT-621 in eosinophilic asthma patients, targeting STAT6, with top-line BREADTH study data expected in late 2027.
Zacks·11d ago
News Placeholder
Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (25 Ratings)
read more...
Benzinga·26d ago
News Placeholder
BTIG Research Reaffirms Buy Rating for Kymera Therapeutics (NASDAQ:KYMR)
BTIG Research reaffirmed a "buy" rating and set a $138.00 price target on shares of Kymera Therapeutics in a research note on Thursday...
MarketBeat·26d ago
News Placeholder
Kymera Therapeutics (KYMR) Upgraded to Buy: Here's Why
Kymera Therapeutics (KYMR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·29d ago
News Placeholder
KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026?
KYMR rallied 82% in a year as KT-621 delivered strong phase Ib BroADen data and earned FDA Fast Track for atopic dermatitis.
Zacks·1mo ago
News Placeholder
Kymera Therapeutics (NASDAQ:KYMR) Trading Down 4.3% - What's Next?
Kymera Therapeutics (NASDAQ:KYMR) Shares Down 4.3% - What's Next...
MarketBeat·1mo ago
<
1
2
...
>

Latest KYMR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.